IAS-USA recommends Descovy (TAF/FTC) for cisgender females: https://jamanetwork.com/journals/jama/fullarticle/2835835
"Additionally, a 2025 analysis provided evidence for an 89% reduction in risk for HIV acquisition in cisgender women who had biomarker evidence of taking at least a mean of 2 doses of tenofovir alafenamide/emtricitabine per week.5 Therefore, tenofovir alafenamide/emtricitabine is now recommended for prevention of HIV acquisition from vaginal exposures for those in whom tenofovir disoproxil fumarate/emtricitabine is contraindicated or undesirable (AIIb)."
------------------------------
Kurtis Mohr, MD, AAHIVS
Orlando FL
------------------------------
Original Message:
Sent: 04-07-2020 13:31
From: Ifeoma Nwofor
Subject: Descovy for Off Label PrEP
Please are there any peer review data on Descovy for off label PrEP use in cisgender women?
------------------------------
Ifeoma Nwofor
Miramar FL
------------------------------